EGF and colorectal carcinoma: From this viewpoint, a recent report evidenced that TAF produce EGF upon Cet treatment, supporting CRC cell growth and rescuing tumor cells from immunotherapy [46]; thus, CRC-TAF should be considered as targets of therapy to overcome this TME-mediated drug resistance.